Pfizer’s Novel CDK 4/6 Inhibitor Palbociclib plus Letrozole Significantly Prolonged Progression-Free Survival in Patients with Advanced Breast Cancer

[Business Wire] – Pfizer Inc. today announced detailed results from the PALOMA-1 study, a randomized Phase 2 study of palbociclib in combination with letrozole. PALOMA-1 achieved its primary endpoint by significantly prolonging progression-free survival more

View todays social media effects on PFE

View the latest stocks trending across Twitter. Click to view dashboard

See who Pfizer is hiring next, click here to view